In June 2022, Quebec passed Bill 96, An Act respecting French, the official and common language of Québec, which amended the Charter of the French Language. These amendments significantly affect labelling and advertising requirements for businesses, including those in the cosmetics industry.
TrailHeads, a U.S. outdoor brand, partnered with Obelis Group to navigate GPSR compliance and launch successfully in the EU, overcoming Amazon-related challenges and accelerating their market entry.
Medical Devices (Pvt) Ltd. partnered with Obelis Group to overcome regulatory challenges and successfully launch in the EU, UK, and Swiss markets with expert support and streamlined compliance.
From May 2025, the EU bans 3-(4′-methylbenzylidene)-camphor in cosmetics. Learn what this means for product compliance and how beauty brands should prepare.
Legacy in-vitro diagnostic devices must comply with IVDR by 26 May 2026. Learn key deadlines, QMS requirements, and how Obelis can support your transition.
Discover Health Canada’s update requiring a Canadian-based representative for foreign cosmetic brands and how Obelis can help with compliance.
Dutch audits reveal non-compliance with EU post-market surveillance (PMS) requirements for medical devices. Learn how to strengthen PMS systems for compliance and safety.
Key February 2025 alert for the cosmetics industry: new EU rules restrict ingredients like Genistein, Kojic Acid, and Alpha-Arbutin under Annex III and ban specific nanomaterials under Annex II.
Discover the information that must be visible on the labels of cosmetic products under article 19 of the EU Cosmetics Regulation.
Learn about the new Article 10a under EU MDR and IVDR, requiring manufacturers to notify authorities and stakeholders of potential medical device or IVD supply interruptions. Understand the scope, notification process, and exemptions, as well as how to comply with these regulations to ensure patient safety and continuity of care.